science

Nipocalimab

Nipocalimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Nipocalimab rather than just read about it. In short: Nipocalimab, sold under the brand name Imaavy, is a monoclonal antibody used for the treatment of generalized myasthenia gravis. It is a neonatal Fc receptor blocker.

Key takeaways

Nipocalimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Nipocalimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Nipocalimab from memory before moving on to harder problems.

Reference excerpt

Nipocalimab, sold under the brand name Imaavy, is a monoclonal antibody used for the treatment of generalized myasthenia gravis. It is a neonatal Fc receptor blocker. It is a high affinity, fully human, aglycosylated, effectorless immunoglobulin G (IgG) anti-FcRn monoclonal antibody. Nipocalimab is a human IgG1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), thereby decreasing the levels of circulating IgG, including pathogenic IgG autoantibodies. Nipocalimab was approved for medical use in the United States in April 2025, and in the European Union in November 2025.

Medical uses Nipocalimab is indicated for the treatment of generalized myasthenia gravis in people aged twelve years of age and older who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

History Nipocalimab was initially developed by Momenta Pharmaceuticals, Inc before it was acquired by Johnson & Johnson in August 2020. Nipocalimab has received rare pediatric disease designation from the US Food and Drug Administration (FDA) for the prevention of hemolytic disease of the fetus and newborn. Additionally, the FDA granted nipocalimab orphan drug designation in hemolytic disease of the fetus and newborn. In 2019, nipocalimab received orphan medicinal product designation by the European Medicines Agency for the treatment of HDFN. In February 2024, nipocalimab was granted breakthrough therapy designation by the US Food and Drug Administration for the treatment of alloimmunized pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn. In August 2024, Johnson & Johnson applied for FDA approval of nipocalimab for the treatment of people living with generalized myasthenia gravis (gMG). The application is based on data from the phase III Vivacity-MG3 study. In November 2024, nipocalimab was granted breakthrough therapy designation by the US Food and Drug Administration as a treatment for adults with moderate-to-severe Sjögren's disease. The decision was based on the results from the phase II DAHLIAS study evaluating the effects of nipocalimab in more than 160 adults with moderately-to-severely active primary Sjögren's disease who were seropositive for anti-Ro60 and/or anti-Ro52 IgG antibodies.

Society and culture

Legal status Nipocalimab was approved for medical use in the United States in April 2025. In September 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Imaavy, intended for the treatment of generalized myasthenia gravis. The applicant for this medicinal product is Janssen-Cilag International NV. Nipocalimab was authorized for medical use in the European Union in November 2025.

Names Nipocalimab is the international nonproprietary name. Nipocalimab is sold under the brand name Imaavy.

Research For hemolytic disease of the newborn, nipocalimab works by decreasing levels of alloantibodies and other circulating IgG antibodies in the mother without impacting immune function. FcRn inhibition is believed to prevent alloantibodies from entering the fetus, which can reduce the risk of hemolytic disease of the newborn.

References

Worked examples

Example 1 — a first encounter with Nipocalimab

Start with the simplest possible case. Write down what Nipocalimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Nipocalimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Nipocalimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Nipocalimab

In research: Nipocalimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Nipocalimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Nipocalimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs developed by Johnson & Johnson, Monoclonal antibodies, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Nipocalimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Nipocalimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Nipocalimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Nipocalimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Nipocalimab in simple terms?

Nipocalimab, sold under the brand name Imaavy, is a monoclonal antibody used for the treatment of generalized myasthenia gravis. It is a neonatal Fc receptor blocker.

Why does Nipocalimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Nipocalimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Nipocalimab.